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2Decreased transketolase activity is an unexplained characteristic of patients with end
stage renal disease (ESRD) and is linked to impaired metabolic and immune function.
Herein we describe the discovery of a link to impaired functional activity of thiamine
pyrophosphate co-factor through the presence, accumulation and pyrophosphorylation
of the thiamine antimetabolite, oxythiamine, in renal failure. Plasma oxythiamine was
increased 4-fold in patients receiving continuous ambulatory peritoneal dialysis (CAPD)
and 15-fold in patients receiving haemodialysis (HD) immediately before a dialysis
session: healthy controls 0.18 (0.11 – 0.22) nM, CAPD, 0.64 (0.48-0.94) nM and HD
(2.73 (1.52-5.76) nM); P<0.001, Mann-Whitney U test. Oxythiamine was converted to the
transketolase inhibitor oxythiamine pyrophosphate (OTPP). Red blood cell OTPP
concentration was increased 4-fold in HD: healthy controls, 15.9 ± 10.4 nM and HD
patients, 66.1 ± 26.7 nM; P<0.001, t-test. This accounted for the concomitant 41% loss of
transketolase activity (mU/mg Hb): healthy controls, 0.410 ± 0.144 and HD, 0.240 ±
0.107; P<0.01, paired t-test. This may be corrected by displacement with excess thiamine
pyrophosphate and explain lifting of decreased transketolase activity by high dose
thiamine supplementation in previous studies. Oxythiamine is likely of dietary origin,
through cooking of acidic thiamine-containing foods. Trace level oxythiamine was not
formed from thiamine degradation under physiological conditions but rather under
acidic conditions at 100 oC. Monitoring of plasma oxythiamine concentration in renal
failure and implementation of high dose thiamine supplements to counter it may help
improve clinical outcome of patients with renal failure.
3Loss of clearance in chronic kidney disease (CKD) leads to accumulation of waste products
from metabolism that increase to potentially damaging concentrations and thereby become
uremic toxins. In end stage renal disease (ESRD) potentially noxious metabolites may
increase >10-fold, particularly preceding a dialysis session. Among classes of uremic toxins
are catabolic and degradation products of essential nutrients and cofactors. Where similar in
structure to their precursor but non-functional, uremic toxins may have potentially damaging
function as anti-metabolites.1
It is known that there is impaired function of the pentosephosphate pathway in
uraemia at the thiamine pyrophosphate (TPP)-dependent step catalysed by transketolase2. The
inhibition of transketolase was reversible although the identity of the inhibitor was difficult to
discern. The inhibitor was of low molecular weight and initially considered to be
guanidinosuccinic acid (GSA). Low levels of GSA in plasma of patients with decreased red
blood cell transketolase activity, lack of correlation of GSA concentration to inhibition of
transketolase activity and failure of GSA to inhibit transketolase activity in red blood cells ex
vivo suggested other compound(s) are likely involved.3-5 Disturbance of levels of
pentosephosphate pathway metabolites in peripheral nerves in vivo regulated by transketolase
activity and recovery of this by HD indicated reversible inhibition of transketolase.
Transketolase activity was also decreased in patients with continuous ambulatory peritoneal
dialysis (CAPD).6 This occurred in the presence of normal levels of plasma thiamine and red
blood cell TPP.4, 7, 8 The mechanism of reversible inhibition of transketolase in renal failure
has remained unresolved for over 40 years.
We hypothesised that transketolase may be inhibited in renal failure by an anti-
metabolite of thiamine which is normally cleared but accumulates to inhibitory levels with
loss of clearance in ESRD. Oxythiamine (4-hydroxythiamine) 9 is pyrophosphorylated by
thiamine pyrophosphokinase to oxythiamine pyrophosphate (OTPP) which inhibits TPP-
4dependent enzymes10-12 – Figure 1. Injection of oxythiamine into rats decreased tissue
transketolase activity.13 We report here the accumulation of oxythiamine in plasma and
related OTPP in red blood cells of patients with ESRD that likely explains the inhibition of
transketolase in renal failure.
RESULTS
We measured plasma thiamine concentration of healthy subjects and patients with ESRD
receiving renal replacement therapy - continuous ambulatory peritoneal dialysis (CAPD) and
haemodialysis (HD) by the conventional thiochrome assay14 – Table 1. The plasma
concentration of thiamine was within the normal range and even increased in CAPD and HD
patients. Oxythiamine is not detectable by the thiochrome assay as it lacks the 4-
aminopyrimidinyl moiety required for thiochrome formation.15 We therefore developed a
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for oxythiamine and
OTPP – Figure 2, a. - d. Oxythiamine were analysed in plasma of ESRD patients receiving
CAPD or HD. Oxythiamine was detectable at trace levels in plasma of healthy people:
median (lower – upper quartile), 0.18 (0.11 – 0.22) nM. In ESRD patients receiving CAPD
and HD, however, this was increased 4-fold, 0.64 (0.48-0.94) nM, and 15-fold, 2.73 (1.52-
5.76) nM, respectively; P<0.001, Mann-Whitney U test – Table 1. In a further group of HD
patients we measured plasma oxythiamine before and after a 4 h dialysis session and found
that oxythiamine decreased by 53 (34 - 64)% during the dialysis session (n = 12, P<0.002,
Wilcoxon Signed Ranks test).
We explored the metabolism of oxythiamine and its effect on thiamine metabolism in
a subgroup of healthy control subjects and HD patients. We measured the concentration of
TPP in red blood cells of healthy subjects and HD patients and found no significant
difference. However, plasma oxythiamine was increased 19-fold in these patients and
5corresponding OTPP concentration in red blood cells was increased 4-fold – Figure 3, a. - c.
OTPP is a reversible competitive inhibitor of transketolase. We measured the transketolase
activity of the red blood cells by the conventional test with lysates prepared ex vivo. Red
blood cell transketolase activity was decreased 41% in HD patients, with respect to healthy
controls – Figure 3d. It was also measured in the presence of excess TPP which is used to
assess the percentage unsaturation of transketolase or “thiamine effect” but will also increase
transketolase activity by displacing competitive inhibitors. With added exogenous TPP there
was no increase in transketolase activity of healthy controls (0.436 ± 0.139 versus 0.410 ±
0.144 mU per mg Hb; P>0.05, paired t-test) but there was a highly significant increase in HD
patients (0.332 ± 0.103 versus 0.240 ± 0.107 mU per mg Hb; P<0.001, paired t-test). This
increase in transketolase activity reflects lifting of reversible competitive inhibition and the
competitive inhibitor TPP is presence in the red blood cell lysate. There was no correlation of
plasma oxythiamine and red blood cell transketolase activity. However, there were highly
significant correlations of red blood cell transketolase activity and OTPP concentration (r = -
0.55, P<0.01; Spearman) and red blood cell OTPP concentration with plasma oxythiamine
concentration (r = 0.79, P<0.001; Spearman).
To deduce if the accumulation of OTPP in red blood cells likely causes significant
inhibition of transketolase clinically, the effect of competitive inhibition of OTPP on
transketolase activity was deduced from enzyme kinetics considerations - Figure 3e.
Comparing the decrease in red blood cell activity of transketolase in HD patients from
healthy controls determined experimentally (Figure 3d) with the computed decrease in
residual transketolase activity by inhibition with OTPP (Figure 3e), it can be seen that
inhibition of transketolase by OTPP accounts for most of the observed decrease of
transketolase activity of red blood cells in HD patients. Experimental transketolase activity is
6decreased 41% and the computed decrease of fractional residual activity of transketolase is
35% in HD patients - Figures 3d and 3e.
For further demonstration that transketolase activity in red blood cells of HD patients
is decreased reversibly by OTPP, we sought to recover transketolase activity by incubation of
red blood cells ex vivo in short term culture with exogenous thiamine. A relatively high
concentration of thiamine (50 μM) was used to drive rapid phosphorylation to TPP and 
displacement of OTPP from transketolase. With thiamine supplementation, red blood cell
transketolase activity was increased to 0.53 ± 0.11 mU/mg Hb (n = 12), similar to that of
healthy controls. In the same incubations, the terminal pentosephosphate pathway metabolite
ribose-5-phosphate (R5P) was quantified with and without 50 μM thiamine. Supplementation 
with thiamine increased the red blood cell concentration of R5P with respect to
unsupplemented controls to levels similar to those of healthy control subjects16: 34.5 ± 14.5
versus 19.1 ± 10.3 nmol/ml packed red blood cells (n = 12; P<0.01, paired t-test).
A possible source of oxythiamine detected clinically is formation by high temperature
processing of thiamine-containing foods under acidic conditions – similar to but not as severe
as conditions of oxythiamine synthesis.15, 17 To model this we incubated 1 μM thiamine in 
water, pH 7.0, at 37 oC and 100 oC, and in 100 mM acetic acid, pH 2.9, at 37 oC and 100 oC
for 1 h. Oxythiamine was detected only in thiamine solution heated at 100 oC and pH 2.9. The
concentration of oxythiamine formed was 0.56 ± 0.06 nM or 0.06% of thiamine. Similar
conversion of dietary thiamine in cooking or commercial food processing with limited
clearance over 2 – 3 days could explain the accumulation of oxythiamine to low nanomolar
levels in ESRD patients.
DISCUSSION
7From the studies herein accumulation and metabolism of the thiamine antimetabolite
oxythiamine in renal failure is a major contributory factor to inhibition of transketolase
activity and block of the pentosephosphate pathway in HD patients. It likely produces similar
effects in renal failure patients with CAPD and pre-dialysis patients. Surveillance of OTPP
levels in red blood cells or oxythiamine levels in plasma may be of benefit. Plasma
oxythiamine concentration correlated strongly and positively with red blood cell OTPP
which, in turn, correlated strongly and negatively with red blood cell transketolase activity.
The lack of correlation of plasma oxythiamine with transketolase activity is likely due to
clearance of oxythiamine in dialysis sessions whereas OTPP and transketolase are both
retained in red blood cells.
The source of oxythiamine in clinical samples is uncertain. Analytical reagent grade
thiamine did not contain detectable oxythiamine impurity. Trace mono-oxygenase
metabolism of thiamine to oxythiamine by human tissues or intestinal bacteria is possible but
unknown; moreover, mono-oxygenases (cytochrome P450 enzymes) tend to be down-
regulated in renal failure.18 The precedent from chemical synthesis and the dependence of
kinetics and product distribution of thiamine degradation on pH and temperature suggest
processing of thiamine under acidic conditions at high temperatures forms oxythiamine.15
Model studies herein support this: oxythiamine was only formed in acidic solution at pH 2.9
heated at 100 oC. pH 2.9 is similar to the acidity of some fruits, diluted vinegar19 and mean
pH of the stomach in the prandial/postprandial period.20 There is, therefore, likely no
significant formation of oxythiamine in the acidic environment of the stomach. Exposure to
oxythiamine is rather likely of dietary origin, formed in thiamine-containing foodstuffs
during home or commercial cooking. The degradation of thiamine in foodstuffs has mostly
been studied for the rapid degradation at high pH which does not form oxythiamine.21
Examples of thiamine containing foodstuffs with natural low pH are fruits and fruit juices;
8canned fruits are heated during commercial processing. Foods may also be made acidic by
vinegar, lemon juice and other acidic culinary additives.19 The use of vinegar in cooking has
been proposed as beneficial in the diet of ESRD patients to decrease potassium and
magnesium content of vegetables22 and to decrease formation of advanced glycation
endproducts (AGEs) in foods.23 This requires reappraisal in light of the current studies. Low
protein diets for renal patients will affect the exposure to oxythiamine if they concurrently
decrease consumption of cooked thiamine-containing acidic foods. The accumulation of
oxythiamine in ESRD patients is due to decreased clearance and elimination by dialysis.
Given the requirement for acidic, high temperature processing for oxythiamine
formation, high dose thiamine administered as a pharmaceutical at ambient temperature does
not lead to oxythiamine formation. Supporting evidence for this is experimental and clinical
studies in renal failure with high dose thiamine or related derivatives where transketolase
activity was increased. 24-26 Maintained low or further decreased transketolase activity would
be expected if formation of oxythiamine had increased.
In preclinical studies administration of oxythiamine decreased the retention of
thiamine in tissues27 and increased the rate of TPP dephosphorylation.28 Oxythiamine was a
weak inhibitor of thiamine transporters29 and potentiated the toxicity of methylglyoxal30
which is also elevated in renal failure and precursor of AGEs.31 Oxythiamine was taken up
and phosphorylated by all tissues of rats except brain; the formation of OTPP was inversely
proportional to TPP content.32 Correspondingly transketolase activity was inhibited in all rat
tissues by oxythiamine administration except the brain,13 likely through formation of OTPP.
OTPP inhibits other TPP-dependent enzymes with lower potency: for mammalian pyruvate
dehydrogenase, the Ki ≈ 70 nM12 and 2-oxoglutarate dehydrogenase complex was little
affected.33
9In clinical studies, decreased transketolase activity leads to impairment of oxidative
and reductive pentose pathway activity, contributing to impaired phagocyte function for
resistance to infection34 and impaired disposal of triosephosphates.35 The latter is associated
with stimulation of mitochondrial dysfunction and formation of oxidative stress, increased
diacylglycerol formation and activation of protein kinase C, activation of the hexosamine
pathway and increased formation of methylglyoxal and AGEs.36 Further disturbance of
thiamine metabolism in renal failure occurs by decreased expression of thiamine transporters
in small intestine, heart, liver and brain and likely decreased availability of thiamine at these
sites.37 Herein we showed that incubation of red blood cells from HD patients ex vivo with
thiamine restored normal levels of transketolase activity and R5P concentration, consistent
with correction of impaired pentose pathway activity.
Plasma oxythiamine was decreased after a dialysis session in HD patients and hence
is cleared by dialysis. Thiamine binds to human serum albumin with a dissociation constants
KD of ca. 1 μM.38 Plasma thiamine measured in the thiochrome assay is the sum of the free
and protein-bound forms. Given the high plasma albumin concentration, 40 mg/ml or ca. 600
μM, most of thiamine is protein-bound in plasma. The affinity of oxythiamine for albumin is 
unknown but oxythiamine had similar urinary excretion characteristics to thiamine in rats and
therefore is likely also bound to albumin.27 This will limit the clearance of oxythiamine in
dialysis.
Previous studies have assessed transketolase deficiency in ESRD by measuring
erythrocyte transketolase activity stimulating index (αETKA). This measures the fractional or 
percentage increase in activity of transketolase on addition of excess cofactor TPP.39 We used
addition of 348 μM herein - ca. 500 fold higher than present physiologically - to provide for
effective and rapid displacement of the OTPP competitive inhibitor. Values of αETKA > 1 
are conventionally assumed to be due to decreased availability of TPP and presence of apo-
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transketolase. In the presence of a competitive inhibitor such as OTPP, however, αETKA also 
reports on inhibition of transketolase where the 500-fold excess TPP displaces the
competitive inhibitor. Consistent with this, herein addition of 500-fold excess TPP increased
transketolase activity in HD patients but not in healthy controls. For αETKA to capture 
reversible inhibition of transketolase, the activity of transketolase is measured immediately
on dilution of red blood cell haemolysate before the inhibitor dissociates from the
holoenzyme by dilution; and when 500-fold excess TPP is added to the haemolysate, 30 min
pre-incubation is performed in the absence of substrate prior to the transketolase activity
measurement to allow for displacement of the inhibitor. When transketolase is in the presence
of substrate, exchange of TPP cofactor and OTPP inhibitor is very slow.40 The absolute level
of transketolase activity relates to metabolic function in the pentosephosphate pathway
whereas αETKA captures the competitive inhibition of transketolase in ESRD patients and 
unsaturation of transketolase by TPP in thiamine deficiency.
Dynamics of TPP cofactor binding to apo-transketolase indicate that if highly diluted
red blood cell lysates are left without substrate at ambient temperature for >30 min prior to
assay, OTPP would be released from holo-transketolase and competitive inhibition lost.40
This may have contributed to discordant reports of decreased transketolase activity in ESRD
patients. Studies by Lonergan and co-workers2, 3 and Kopple et al.41 used a modified method
of transketolase activity assessment developed by Dreyfus42 which was subsequently found to
lack specificity and reproducibility43-45 and is no longer used. Inhibition of transketolase
would have been lost if high dilution of red blood cell lysate was prepared without immediate
assay of transketolase activity such that OTPP dissociated from the holoenzyme.
In clinical translation, dietary deficiency of thiamine - leading to Beriberi and
Wernicke–Korsakoff syndrome if untreated, may be conveniently diagnosed by urinary
excretion of thiamine where excretion of ≤0.20 µmol/24 h reflects thiamine nutritional
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deficiency.46 In ESRD patients, plasma thiamine measured by the thiochrome assay is an
expected surrogate measure of this. Recent studies in diabetes and CKD suggest there are
also abnormalities of thiamine transport due to tissue-specific down regulation of thiamine
transporters.14, 37, 47 Measurement of renal clearance of thiamine is a sensitive clinical marker
of this.14 Red blood cell transketolase activity is valuable to assess impact on the
pentosephosphate pathway and αETKA to explore cause of transketolase activity deficit.48
Where competitive inhibition of transketolase by OTPP or similar antimetabolite is
suspected, care is required to ensure the inhibitor does not dissociate from the holoenzyme
before the activity is recorded. Plasma oxythiamine offers an assessment of oxythiamine
exposure with analytical standard available commercially.
In summary, transketolase activity is likely impaired in red blood cells in ESRD
patients by inhibition by the antimetabolite OTPP. The recommendation for patients with
stage 3 – 5 CKD to take a supplement of the daily reference intake (DRI)49 of 1.1 – 1.3 mg
thiamine may be insufficient given the increased concentration of OTPP in renal failure. The
remedy to the antimetabolite effects of oxythiamine accumulation is pharmaceutical doses of
thiamine to produce increased TPP for OTPP displacement from transketolase. Thiamine (30
- 45 mg per day equivalent) in HD patients was studied and found to alleviate transketolase
deficiency.24 These remedial effects found were consistent with reversal of OTPP
antimetabolites effects but oxythiamine was not determined and the minimum dose of
thiamine required for benefit is uncertain. High dose thiamine supplementation in renal
failure is deserving of further attention to assess if it can consistently alleviate the metabolic
impairment linked to transketolase insufficiency.
METHODS
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Materials
Thiamine, TPP (≥ 95%), oxythiamine chloride hydrochloride (HPLC grade, ≥ 95%) and D-
ribose-5-phosphate, disodium salt dihydrate (≥99%) were purchased from Sigma-Aldrich 
(Poole, U.K.). [4,5,5–Methyl-13C3] thiamine chloride (99 atom %) was purchased from
Cambridge Isotope Laboratories (Andover, USA). OTPP was prepared from oxythiamine and
purified by HPLC as described.50
Healthy subject and patients
Peripheral venous blood samples were collected from healthy human subjects and patients
with stage 5 CKD receiving CAPD or HD renal replacement therapy. For HD patients, blood
samples were collected immediately before and after a 4 h dialysis session. Samples were
collected using EDTA as anticoagulant. Blood cells were sedimented by centrifugation
(2000g, 10 min) and plasma removed. White blood cell buffy coast was removed and red
blood cells retained. Clinical characteristics of the participants are given - Table 1. Healthy
human subjects and patients were recruited at the University Hospitals Coventry &
Warwickshire NHS Trust, Coventry, U.K., after written informed consent. The study was
approved by National Research Ethics Service Committee West Midlands - Coventry &
Warwickshire, (REC 05/Q202/26), and Black Country Research Ethics Committee
(REC:09/H1202/113). Plasma and red blood cells were stored at -80oC until analysis.
Red blood cell incubation ex vivo
Red blood cells from HD patients were washed three times with 4 volumes of phosphate-
buffered saline, and with a final wash of 4 volumes of Krebs-Ringer phosphate buffer (120
mM NaCl, 4.8 mM KC1, 1 mM CaCl2, 1.2 mM MgSO4, 16.5 mM NaH2PO4/ Na2HPO4, pH
7.4, and 5 mM D-glucose). Red blood cell suspensions (50% v/v; 0.25 ml) were then
13
incubated for 2 h at 37 oC in a shaking water bath with and without 50 μM thiamine, as 
described.16 Cells were then either collected by centrifugation (2000g, 10 min, room
temperature) and transketolase activity assayed or de-proteinised by addition of ice-cold
perchloric acid (250 µl, 0.6 M) and analysed for R5P – see below.
Assay of thiamine and TPP by the HPLC thiochrome method.
Plasma thiamine and red blood cell TPP were determined by HPLC with fluorimetric
detection as previously described.14 Briefly, plasma was used without further processing. Red
blood cells were washed 4 times with isotonic saline, lysed with 4 volumes of water and
membranes sedimented by centrifugation (6000, 10 min, 4 oC). The supernatant hemolysate
was retained. Plasma diluted 5-fold in water (50 μl) or hemolysate (25 μl) was mixed with 
20% (w/v) trichloroacetic acid (TCA) for de-proteinisation; and internal standard,
chloroethylthiamine (1 μM, 10 μl), added and mixed again. Samples were kept on ice for 10
min and then precipitate was sedimented by centrifugation (6000g, 4 ºC, 10 min). The
supernatant was removed and adjusted to pH 4.5 by addition of 2 M sodium acetate (7 μl for 
plasma,10 μl for haemolysate) and spin-filtered (0.2 µm, 4000 g, 4 ºC, 10 min). The filtrate 
(40 µl) was analysed by HPLC. Chromatographic conditions used were optimized for
thiochrome recovery. Column: 3 x 150 mm C18 column with 3.5 µm particle size and 3 x 20
mm guard column (Xbridge; Waters, U.K.). Mobile phases: A – 10 mM K2HPO4/ KH2PO4 in
water at pH 8.4; B – 10 mM K2HPO4/ KH2PO4 in 50% methanol at pH 8.4; and C – 30%
isopropanol in water with 0.1% trifluoroacetic acid. The flow rate was 0.5 ml/min. The
elution profile was: 0 min, 95% A + 5% B; 0 – 20 min, a linear gradient of 5 – 100% B; 20 –
32 min 100% C (column washing); and 32 – 48.5 min 95% A + 5% B (re-equilibration).
Samples were derivatised with NaOH-K3[Fe(CN)6] solution prepared and mixed with
samples immediately prior to injection. The autosampler was programmed to mix 40 µl 15%
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NaOH and 10 µl 1% K3[Fe(CN)6], then add 10 µl of this to 40 µl of the sample, and finally
25 µl of the derivatised sample injected onto the column for each analysis. Thiochromes
formed by derivatisation were detected by fluorescence spectrophotometer at excitation 365
nm and emission 439 nm. The retention times, limits of detection, interbatch coefficient of
variation and recoveries were: thiamine 13.1 min, 36 fmol, 1.1% and 97%; and TPP 4.5 min,
51 fmol, 2.9% and 94%. Stock solutions of thiamine and TPP were calibrated by
spectrophotometry assuming extinction coefficients of ε233 = 14.2 and ε247 =13.0 mM-1cm-1,
respectively.51 Oxythiamine is not detectable by the thiochrome assay as it lacks the 4-
aminopyrimidinyl moiety required for thiochrome formation.15
Assay of red blood cell transketolase activity and ribose-5-phosphate concentration
Red blood cell transketolase activity was determined by the method of Chamberlin et al.52 To
determine the thiamine effect, transketolase activity was measured with and without addition
of 348 μM TPP. Haemolysate was incubated with and without TPP for 30 min in the absence 
of substrate prior to the transketolase activity measurement to allow for displacement of the
putative OTPP inhibitor by TPP.
Red blood cell R5P concentration was determined by negative ion LC-MS/MS, as we
previously described,53 confirming quantitation by standard addition analysis of authentic
analyte.
Assay of oxythiamine and red blood cell OTPP were determined by liquid
chromatography-tandem mass spectrometry
Plasma oxythiamine and red blood cell OTPP were determined by LC-MS/MS, operating in
positive ion, multiple reaction monitoring (MRM) mode. Chromatographic and mass
spectrometric detection conditions are given in Table 2. Detection were normalised to [4,5,5–
15
methyl-13C3] thiamine internal standard and analyte amounts deduced from calibration curves
constructed by assay of 0.01 – 2.0 pmol oxythiamine and 0.1 – 2 pmol OTPP. For plasma
oxythiamine, plasma (50 µl) was spiked with 2 pmol of [13C3]thiamine and deproteinised by
addition of 20 µl 20% trichloroacetic acid (TCA). The precipitate was centrifuged (20,000g,
4ºC, 10 min) and the supernatant removed, filtered (0.2 µm pore size) and an aliquot (45 µl
analysed by LC-MS/MS. For red blood cell OTPP, packed red blood cells (50 µl) were
spiked with 0.1 pmol of [13C3]thiamine (5 µl, 0.02µM) and lysed and de-proteinized by
addition of 40 µl 10% TCA. The samples were placed on ice for 10 min and then membranes
and protein precipitate sedimented by centrifugation (20,000g, 10 min at 4°C). The
supernatant was removed filtered (0.2 µm pore size) and an aliquot (40 µl) analysed by LC-
MS/MS. There was no degradation of thiamine to oxythiamine in pre-analytic processing but
thiamine degraded partly to oxythiamine in the electrospray source in mass spectrometric
detection and so thiamine and oxythiamine were resolved chromatographically to avoid
interference – see Figure 2, a. and b. In the assay of OTPP, TPP and OTPP were only partly
resolved chromatographically and TPP partly degrades to OTPP in the electrospray sourced
of the mass spectrometry. The fraction of TPP degrading to OTPP was constant in analysis of
standards and this was used to correct OTPP detected in samples for the contribution
produced from TPP degradation to OTPP during electrospray ionization.
Calculation of fractional residual activity of transketolase in the presence of
oxythiamine pyrophosphate
The dependence of apparent reaction velocity, Vapp, of the transketolase-catalysed reaction in
the presence of a fixed, steady-state concentration of transketolase and substrates and varied
TPP concentration is given by the equation: Vapp = kapp[TPP]/(KTPP + [TPP]), where kapp is
the apparent pseudo first order rate constant, KTPP is the dissociation constant for the
16
transketolase /TPP complex and [TPP] is the steady-state concentration of TPP.54 In the
presence of the competitive inhibitor OTPP, this is modified to Vapp,OTPP =
kapp[TPP]/(KTPP(1+[OTPP]/KOTPP) + [TPP]), where KOTPP is the dissociation constant for the
transketolase /OTPP complex and [OTPP] is the steady-state concentration of OTPP. The
fractional residual activity of transketolase in the presence of a given concentration of OTPP
– the proportion of the total transketolase remaining – is given by Vapp,OTPP/ Vapp
= (KTPP + [TPP])/(KTPP(1+[OTPP]/KOTPP) + [TPP]). The fractional activity of transketolase
may be deduced for each subject and HD patient by estimation of [TPP] and [OTPP] and
assuming values of KTPP and KOTPP: TPP = 610 nM and KOTPP  ≈ 15 nM.10, 11
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Table 1 │Characteristics of healthy subjects and ESRD patients on dialysis. 
Variable Healthy controls CAPD HD
Gender (M/F) 8/8 7/9 8/8
Age (years) 48 ± 5 43 ± 15 49 ± 6
BMI (kg/m2) 25.5 ± 3.2 25.6 ± 3.0 26.2 ± 3.6
Plasma creatinine (µM) 71 ± 17 655 ± 249 677 ± 268
Plasma albumin (mg/ml) 45.6 ± 3.2 35.6 ± 6.9 43.1 ± 3.5
Plasma thiamine (nM) 5.1 (4.3- 9.7) 31.8 (18.0 – 53.5)*** 51.1 (20.1 – 83.0)***
Plasma oxythiamine (nM) 0.18 (0.11 – 0.22) 0.64 (0.48 – 0.94)*** 2.73 (1.52 – 5.76)***,OOO
Data are mean ± SD or median (lower – upper quartile). Significance: *** and OOO, P<0.001 with respect to healthy controls and CAPD,
respectively. A second study group of HD patients has plasma analysed for plasma oxythiamine before and after a dialysis session and
characteristics were: gender (M/F) 6/6, age 49 ± 24 yrs, BMI 26.4 ± 7.9 kg/m2, and plasma albumin 40.5 ± 4.0 mg/ml (n = 12).
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Table 2 │ Liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection
of thiamine metabolites.
Analyte Rt (min) Molecular ion>
fragment ion
transition (Da)
Collision
energy
(eV)
Cone
voltage
(V)
Method 1 Method
2
Oxythiamine 12.9 36.5 265.9 > 123.0 18 40
Thiamine 13.9 39.5 264.9 > 122.0 18 16
4,5,4-Methyl-
[13C3]-thiamine 13.9 39.5 267.9 > 122.0 18 16
OTPP --- 32.7 425.9 > 123.0 26 44
TPP --- 32.7 424.9 > 122.0 26 44
Chromatographic conditions: Method 1. Column - two graphitic HypercarbTM columns
(Thermo) in series, 5 µm particle size, 2.1 x 50 mm and 2.1 mm x 250 mm. The mobile phase
was: 0.1% trifluoroacetic acid (TFA) with a custom gradient of acetonitrile (MeCN); 0.2
ml/min. Elution programme: 0 – 2 min, 0% MeCN; 2 – 15 min, 0 – 18% MeCN; and 15 – 18
min, 18 – 50% MeCN. After each injection the columns were cleaned by elution of column 1
and then column 2 with 50% tetrahydrofuran in 0.1% TFA for 5 min, 0.2 ml/min) and then
re-equilibrated with 0.1% TFA in water, 0.4 ml/min, for 15 min. LC-MS/MS was performed
with an Acquity-Quattro Premier (Waters) with electrospray source temperature 150 oC,
desolvation gas temperature 500 oC with desolvation and cone gas flows of 1000 and 150 L/h
respectively, and capillary voltage was 0.6 kV. Method 2. As for Method 1 except elution
programme: 0 – 2 min, 0% MeCN; 2 – 45 min, 0 – 5% MeCN. LC-MS/MS was performed
with an Acquity-Xevo-TQS (Waters) to meet the increased sensitivity of detection response
required with instrument settings as above except capillary voltage was 2.5 kV.
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FIGURE LEGENDS
Figure 1 | Formation, metabolism and antimetabolite activity of oxythiamine. Pathways
of thiamine metabolism, oxythiamine formation and metabolism to antimetabolite
oxythiamine pyrophosphate.
Figure 2 | Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay of
oxythiamine and oxythiamine pyrophosphate. Detection of oxythiamine, multiple reaction
monitoring chromatogram, 265.9 > 123.0 Da: a. Analytical standard containing 100 fmol
oxythiamine and 100 fmol thiamine. b. Detection of oxythiamine in plasma of a HD patient.
* indicates oxythiamine formed from thiamine in the electrospray ionisation source.
Detection of oxythiamine pyrophosphate (OTPP), multiple reaction monitoring
chromatogram, 425.9 > 123.0 Da: c. Analytical standard containing 1.5 pmol fmol OTPP. b.
Detection of OTPP in red blood cells of a HD patient.
Figure 3 | Metabolism of oxythiamine to oxythiamine pyrophosphate (OTPP) and
inhibition of red blood cell transketolase in healthy human subjects and HD patients. a.
red blood cell (RBC) thiamine pyrophosphate (TPP), healthy controls, 692 ± 185 nM, and
HD patients, 782 ± 176 nM (n = 13; P>0.05, t-test). b. Plasma oxythiamine concentration -
Healthy controls, 0.19 ± 0.11 nM, and HD patients, 3.74 ± 2.97 nM (P<0.001, t-test). c. Red
blood cell OTPP – Healthy controls, 15.9 ± 10.4 nM, and HD patients, 66.1 ± 26.7 (P<0.001,
t-test). d. Red blood cell transketolase (TK) activity - Healthy subjects, 0.410 ± 0.144 mU/mg
Hb, and HD patients, 0.240 ± 0.107 mU/mg Hb (- 41%, P<0.002, t-test). e. Fractional
residual red blood cell transketolase activity – see Methods section. Data are mean ± SD (n =
10, healthy subjects n = 13, HD patients).
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